查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1917696

短腸症候群市場－2026-2031年預測

Short Bowel Syndrome Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 153 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計短腸症候群市場將從 2025 年的 19.53 億美元成長到 2031 年的 29.06 億美元，複合年成長率為 6.85%。

受臨床、商業性和監管因素的共同影響，短腸症候群(SBS) 市場預計將穩定成長。市場擴張主要與患者群體不斷擴大、臨床認知度不斷提高以及治療性介入管線不斷推進密切相關。儘管全部區域預計都將實現成長，但市場發展軌跡仍受到商業性和研究環境中許多機會和挑戰的雙重影響。

市場成長的主要催化劑是全球胃腸道疾病盛行率的上升，而這些疾病正是短腸症候群（SBS）的主要病因。克隆氏症、腸扭轉和其他嚴重的腸道疾病通常需要大規模的手術切除，導致腸道功能障礙。這些基礎疾病發生率的上升（部分原因是生活方式的改變）直接擴大了可接受SBS治療的患者群體。這持續催生了對有效治療策略的臨床需求，進而推動了市場發展。

為配合此人口統計數據，各方正齊心協力提高醫護人員與病患對疾病的認知。由專業組織和協會主導的宣傳教育活動發揮關鍵作用，這些活動旨在教育相關人員了解腸道功能障礙、短腸症候群（SBS）給患者帶來的巨大負擔以及系統性護理過渡的重要性。透過改善診斷和治療模式，這些努力顯著提高了患者識別率、護理標準，並促進了現有和新興治療方法。

此外，市場發展得益於大量的科學研究和臨床活動。政府和機構的資金支持著旨在開發創新治療方法的先進研究計劃，包括新型藥物以及組織工程等突破性方法的研究。同時，由於大型製藥和生技公司積極參與臨床開發，市場競爭格局也十分活躍。多種在臨床實驗藥物，包括長效類似物和其他標靶治療，正處於研發階段，這預示著治療方法方向正朝著更有效、更便捷的方向發展。新藥的商業化以及新型化合物獲得監管部門核准預計將成為擴大治療選擇和市場規模的關鍵成長要素。

然而，市場潛力受到多種限制因素的限制。核准藥物療法的數量有限，尤其是在發展中地區，這限制了患者的用藥途徑。此外，某些藥物的副作用需要仔細的臨床評估，以確保患者獲得良好的獲益風險比。除了這些藥理學的挑戰外，不同地區醫療基礎設施和報銷制度的差異也是阻礙市場普遍滲透和資源匱乏地區成長的障礙。

從地理角度來看，北美預計將繼續佔據顯著的市場佔有率。這一主導地位得益於短腸症候群（SBS）的高發生率、先進的醫療基礎設施以及對生物醫學研究的大力投入。該地區擁有許多積極投資於研究和臨床試驗的關鍵市場參與者，從而創造了有利於創新和商業發展的環境。該地區臨床專業知識和研究資金的集中也持續吸引大量的市場活動。

總之，短腸症候群市場正處於成長軌道上，其成長動力源自於不斷成長的臨床需求和科學進步。伴隨相關胃腸道疾病的患者群體不斷擴大，為市場需求提供了堅實的基礎。此外，策略性的宣傳活動和積極的在臨床實驗治療方案（由研究經費支持）也進一步強化了這項需求。市場相關人員正抓住機遇，利用創新治療方法滿足尚未滿足的重大需求，同時也努力應對藥物可近性、安全性以及全球醫療保健差異等挑戰。該市場的未來發展將取決於臨床研究成果能否成功轉化為核准、可及且耐受性良好的治療方法，從而顯著改善患者的治療效果。

本報告的主要優勢：

  • 深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要企業的策略舉措，並了解透過正確的策略進入市場的可能性。
  • 市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
  • 可操作的建議：利用這些見解，在動態環境中製定策略決策，發展新的商業機會和收入來源。
  • 受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

企業使用我們的報告的目的是什麼？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

  • 2021年至2025年的歷史數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區（包括國家）分類的收入和預測評估
  • 公司概況（策略、產品、財務資訊）及主要發展動態。

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議

第4章 技術展望

第5章短腸症候群藥物市場

  • 介紹
  • 類升糖素肽-2 (GLP2)
  • 生長激素
  • 麩醯胺酸
  • 其他

第6章短腸症候群市場依通路分類

  • 介紹
  • 醫院藥房
  • 零售藥房
  • 線上銷售

第7章短腸症候群市場（按地區分類）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第8章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第9章：公司簡介

  • Takeda Pharmaceutical Company
  • OxThera Inc.
  • VectivBio AG
  • Merck KGaA
  • Ardelyx
  • Zealand Pharma
  • Nestle Health Science
  • Hanmi Pharm.Co., Ltd

第10章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061615639

The short bowel syndrome market, at a 6.85% CAGR, is projected to increase from USD 1.953 billion in 2025 to USD 2.906 billion in 2031.

The Short Bowel Syndrome (SBS) market is poised for steady growth, driven by a confluence of clinical, commercial, and regulatory factors. The market's expansion is fundamentally linked to an increasing patient population, heightened clinical awareness, and a progressive pipeline of therapeutic interventions. While growth is anticipated across key regions, the market trajectory is influenced by both significant opportunities and inherent challenges that shape the commercial and research landscape.

A primary catalyst for market growth is the rising global prevalence of gastrointestinal disorders, which are a leading cause of SBS. Conditions such as Crohn's disease, volvulus, and other severe intestinal pathologies often necessitate extensive surgical resection, resulting in intestinal failure. The increasing incidence of these underlying disorders, partly attributed to evolving lifestyle factors, is directly enlarging the addressable patient pool for SBS therapies. This establishes a sustained clinical demand for effective management strategies, fueling market development.

Complementing this demographic driver is a concerted effort to elevate disease understanding among both healthcare providers and patients. Awareness initiatives, spearheaded by specialized organizations and professional societies, are playing a pivotal role. These programs focus on educating stakeholders about intestinal failure, the significant patient burden associated with SBS, and the importance of structured care transitions. By enhancing the diagnostic and treatment paradigm, these initiatives are instrumental in improving patient identification, care standards, and ultimately, the adoption of available and emerging therapies.

The market is further energized by significant scientific and clinical activity. Government and institutional funding is supporting advanced research projects aimed at developing innovative treatments. These include investigations into novel pharmacological agents as well as groundbreaking approaches like tissue engineering. Concurrently, the competitive landscape is dynamic, with key pharmaceutical and biotechnology companies actively engaged in clinical development. The pipeline features several investigational drugs, including long-acting analogs and other targeted therapies, indicating a move towards more effective and convenient treatment modalities. Product launches and the pursuit of regulatory approvals for new compounds are anticipated to be major growth levers, expanding treatment options and market scope.

However, the market's potential is tempered by several restraining factors. A limited number of approved pharmacotherapies, particularly in developing regions, constrains patient access. Furthermore, the side effect profiles associated with certain medications necessitate careful clinical evaluation to ensure a favorable benefit-risk ratio for patients. These pharmacological challenges, combined with disparities in healthcare infrastructure and reimbursement frameworks across different geographies, present barriers to universal market penetration and limit growth in under-resourced settings.

From a geographical perspective, North America is positioned to maintain a substantial market share. This prominence is underpinned by a well-established prevalence of SBS, advanced healthcare infrastructure, and robust investment in biomedical research. The region benefits from the presence of leading market players who are actively investing in research and clinical trials, fostering an ecosystem conducive to innovation and commercial development. The concentration of clinical expertise and research funding in this region continues to attract significant market activity.

In conclusion, the Short Bowel Syndrome market is on a growth trajectory shaped by increasing clinical need and scientific advancement. The expansion of the patient population due to related gastrointestinal disorders provides a solid foundation for demand. This is amplified by strategic awareness campaigns and a vibrant pipeline of investigational therapies supported by research funding. Market players are navigating a path defined by the opportunity to address a serious unmet medical need with innovative treatments, while simultaneously contending with challenges related to drug accessibility, safety, and global healthcare inequities. The evolution of this market will hinge on the successful translation of clinical research into approved, accessible, and well-tolerated therapies that meaningfully improve patient outcomes.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Short Bowel Syndrome Market Segmentation:

BY DRUG CLASS

  • Glucagon-like Peptide-2 (GLP2)
  • Growth Hormone
  • Glutamine
  • Others

BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

BY GEOGRAPHY

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SHORT BOWEL SYNDROME MARKET BY DRUG CLASS

  • 5.1. Introduction
  • 5.2. Glucagon-like Peptide-2 (GLP2)
  • 5.3. Growth Hormone
  • 5.4. Glutamine
  • 5.5. Others

6. SHORT BOWEL SYNDROME MARKET BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Hospital Pharmacies
  • 6.3. Retail Pharmacies
  • 6.4. Online Sales

7. SHORT BOWEL SYNDROME MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Takeda Pharmaceutical Company
  • 9.2. OxThera Inc.
  • 9.3. VectivBio AG
  • 9.4. Merck KGaA
  • 9.5. Ardelyx
  • 9.6. Zealand Pharma
  • 9.7. Nestle Health Science
  • 9.8. Hanmi Pharm.Co., Ltd

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations